Bryan is a Partner at Venrock, joining the firm as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of health care investments. Bryan is currently Chairman of the Board of Directors of Achaogen, Castlight Health, and Ironwood Pharmaceuticals (NASDAQ: IRWD) and also serves on the Board of several other private companies, including Coderyte, Intarcia, Kyruus and Tandem Diagnostics. Past investments include athenahealth (NASDAQ: ATHN), Illumina (NASDAQ: ILMN), Sirna Therapeutics (acquired by Merck) and Xenoport (NASDAQ: XNPT). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has been the highest-ranking health care investor on Forbes’ Midas List since 2008. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.
Vijay Lathi is a Managing Director focused on information convergence and diagnostics investments. Vijay joined Sprout in 1998, was promoted to Partner in 2003, and was one of the founders of New Leaf in 2005. Prior to focusing on information convergence, Vijay’s investment activity covered a range of healthcare technologies including HCIT, diagnostics and therapeutic platforms, and was the founding investor in both Ilypsa (sold to Amgen) and Relypsa (RLYP). Prior to joining Sprout, Vijay was an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and analyst at Cornerstone Research, a consulting firm focused on financial and economic analysis for business litigation. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in Chemical Engineering, with an emphasis on the application of engineering to life science technology.
Dr. Gary L. Gottlieb is the CEO of Partners In Health. From 2010 until February of 2015, he served as president and CEO of Partners HealthCare, the parent of the Brigham and Women’s and Massachusetts General Hospitals, operating the largest health care delivery organization in New England and among the nation’s largest nonprofit biomedical research and training enterprises. Dr. Gottlieb is a professor of psychiatry at Harvard Medical School and a member of the Institute of Medicine of the National Academies. He served as president of Brigham and Women’s/Faulkner Hospitals, as president of North Shore Medical Center, and as chairman of Partners Psychiatry. Prior to coming to Boston, Dr. Gottlieb spent 15 years in positions of increasing leadership in health care in Philadelphia. As a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania, he earned an M.B.A with distinction in health care administration from the Wharton Graduate School of Business Administration. Dr. Gottlieb is a member of the National Academy of Medicine and serves on the Board of the Federal Reserve Bank of Boston.
Dan joined Highland in 1996 as a Partner to establish and build the firm’s internet investment practice. He is leading the firm’s expansion efforts into China. He continues to be an active investor focusing on technology and consumer investments with specific experience and interest in internet, digital marketing and media technologies. Dan has led the firm’s investments and served on the boards of a number of successful companies including: Amp Resources (acquired by Enel), Ask Jeeves (IPO), BeFree (IPO), Coremetrics (acquired by IBM), eToys (IPO), Fastclick (IPO, acquired by ValueClick), Gamesville (acq'd by Lycos), Lycos (IPO), MapQuest (IPO, acquired by AOL), N2 Broadband (acquired by TANDBERG), Navic Networks (acquired by Microsoft), NextCard (IPO), NYTimes Digital (acquired by New York Times), Qihoo 360 (IPO), Quote.com (acquired by Lycos), Raindance (IPO), RoweCom (IPO), StyleFeeder (acquired by Time, Inc.) and YogaWorks (acquired by Great Hill Partners). His current portfolio includes Beyond the Rack, CMI Marketing, HourlyNerd, Rent The Runway, ThredUp, and Yipit. Dan has been recognized by the prestigious Forbes Midas List as one of the top venture capitalists in the industry. Prior to joining Highland in 1996, Dan was a Partner at CMG@Ventures where he co-led the partnership's investment activities in early-stage internet companies. Dan earned a B.S., Computer Science and Marketing from Boston College and an M.B.A. from Harvard Business School.
Robert is Co-Founder of Lux Capital and focuses on ventures in healthcare. Robert graduated from the University of Virginia and has been a member of the Regional Selection Committee for UVA’s Jefferson Scholars Foundation. Robert was also a member of Motorola’s Research Visionary Board and an invited lecturer at the Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, Yale University, Georgetown, and the University of Virginia. He has been published in Journal of Biomedical Materials Research (Applied Biomaterials) and Nature Biotechnology. Robert was Founding CEO and is currently on the Board of Directors at Harvard Medical School spinout Genocea Biosciences (vaccine discovery). In 2009, Robert was nominated as Biotech CEO of the Year at the World Vaccine Congress. In 2010, Robert was selected as one of the “100 of the Most Inspiring People” by PharmaVoice Magazine. Robert is Co-Founder of Lux Research (emerging technology research), Founding CEO of Kala Pharmaceuticals (mucosal drug delivery), and has served as an Advisor to the Bill & Melinda Gates Foundation.
Donald Trigg serves as Senior Vice President and President of Cerner Health Ventures. In his role, he focuses on analyzing early market segment and top health system opportunities and then working with Chief Executive Neal Patterson to advance a leadership position within them. Mr. Trigg rejoined Cerner in 2012 after the successful sale of Natural Language Processing (NLP) category leader CodeRyte to 3M’s healthcare division. During his time at the company, CodeRyte saw triple-digit bookings growth including the largest quarter in company history leading up to the acquisition in Q2 2012. Before joining CodeRyte, Trigg spent more than seven years at Cerner where he served in a variety of executive roles, including Managing Director of the company’s operations in the United Kingdom and Ireland in London, England; General Manager for the Kansas City, Missouri, geography; management of corporate communications and marketing operations worldwide; and creation of Cerner’s government practice. Beyond his decade in healthcare IT, Trigg also brings a broad public policy background to Cerner at a time of increased government presence in healthcare. He worked for President George W. Bush for almost four years, running the policy arm of the Department of Commerce for Secretary Donald Evans, working as a senior adviser in Austin, Texas, for the 2000 Bush for President campaign and serving on the 2001 Bush-Cheney transition team. Mr. Trigg also had a multi-year tenure on Capitol Hill, working in a series of senior policy positions in the U.S. Senate and the U.S. House. Mr. Trigg serves as a member of the advisory board of Western Governors University (WGU) and also sits on the Greater Kansas City board of the American Red Cross. Trigg graduated from St. Lawrence University in Canton, N.Y with a BA in Economics and U.S. History.
Graham is the Co-Founder and the CEO of Kyruus. Prior to Kyruus, Graham was a Venture Executive at Highland Capital Partners where he co-founded Generation Health and served as the company’s Chief Medical Officer through its acquisition by CVS Caremark. He is also the Co-Founder of SynapDx, a molecular diagnostic company focused on developing a blood test to enable the earlier detection of Autism Spectrum Disorders. Graham completed his clinical training in internal medicine and cardiology at Beth Israel Deaconess Medical Center and Harvard Medical School, where he also served as Chief Medical Resident. Graham completed his BA and MD degrees at Brown University, and received his MBA from Harvard Business School.
Julie is a Co-Founder of Kyruus and serves as the company’s Chief Product Officer. She was previously the VP of Clinical Product Strategy at Generation Health, where she oversaw the development of the company’s clinical programs and data analytics platform. Julie also led the Product Management efforts at Knome, the private arm of George Church’s Personal Genome Project, where she developed and launched a bioinformatics platform for conducting individualized genomic sequence analysis. Julie’s passion for data-driven businesses began as a software engineer at Endeca Technologies, where she ultimately helped to lead Endeca’s efforts in the health care industry as a Sales Engineer for Strategic Accounts. Julie has an undergraduate degree in computer science from MIT, an MS in biomedical sciences from the Harvard-MIT HST Program, and an MBA from the MIT Sloan School of Management.